Several other research firms also recently weighed in on GXI. JPMorgan Chase & Co. set a €87.70 ($104.40) target price on Gerresheimer and gave the company a buy rating in a research report on Thursday, January 4th. Berenberg Bank set a €75.00 ($89.29) price objective on Gerresheimer and gave the company a buy rating in a research report on Friday, December 8th. Kepler Capital Markets set a €65.00 ($77.38) price objective on Gerresheimer and gave the company a sell rating in a research report on Friday, November 3rd. Deutsche Bank set a €64.00 ($76.19) price objective on Gerresheimer and gave the company a neutral rating in a research report on Friday, December 1st. Finally, Commerzbank set a €77.00 ($91.67) price objective on Gerresheimer and gave the company a buy rating in a research report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. Gerresheimer has a consensus rating of Hold and an average price target of €70.62 ($84.07).
Gerresheimer (GXI) opened at €71.65 ($85.30) on Wednesday. The firm has a market capitalization of $2,250.00 and a price-to-earnings ratio of 50.82. Gerresheimer has a 52-week low of €59.97 ($71.39) and a 52-week high of €78.25 ($93.15).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.